Abstract 1570P
Background
Patients with Esophageal Cancer (EC) have variable responses to (chemo)radiotherapy. A reliable early prediction of outcomes allows for enhancing treatment efficacy and follow-up monitoring. DCE-MRI can provide information regarding tumor perfusion and permeability and has shown prognostic value in certain tumor types. Our aim was to investigate the potential application of DCE-MRI parameters as predictors for progression-free (PFS) and overall survival (OS) inpatients with EC treated with concurrent chemoradiation (CRT).
Methods
This study involved fifty-two patients with esophageal cancer and treated with CRT. The patients underwent DCE-MRI before CRT (pre-CRT) in three weeks and three weeks after starting CRT (post-CRT). Patients were grouped into high and low risk groups according to the cut-off value of best OS and PFS respectively. The correlations between quantitative parameters of DCE-MRI (pre-Ktrans, post-Ktrans and the changes and ratios of parameters (ΔiKtrans, riKtrans), and OS/PFS were calculated and compared between two-time frames in two groups, respectively. The K-M method was used to calculate the survival curve, and the log-rank method was used to compare differences in the survival curves.
Results
The level of pre-CRT Ktrans was positively associated with OS (cutoff value=70.53/min, p=0.113) and PFS (cutoff value=70.53/min, p=0.026). The level of post-CRT Ktrans was impaired associated with OS (cutoff value=45.60/min, p=0.001) and PFS (cutoff value=45.60/min, p=0.003). Level of riKtrans was impaired associated with OS (cutoff value=0.374, p=0.024) and PFS (cutoff value=0.374, p=0.040). The level of ΔiKtrans was impaired associated with OS (cutoff value=4.5/min, p=0.048) and PFS (cutoff value=0.595/min, p=0.056).
Conclusions
This study suggests an important role for DCE-MRI parameter Ktrans as a predictor of outcome in Esophageal Cancer patients treated with CRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Liu.
Funding
NA.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1569P - The CODRP model for predicting drug sensitivity in patient-derived 3D gastric cancer cells
Presenter: Dong Woo Lee
Session: Poster session 22
1571P - Exploration of immune and metabolism gene signature for prognosis of esophageal carcinoma and establishment of a combined prediction model
Presenter: Hao Wu
Session: Poster session 22
1572P - Impact of HER2 and PD-L1 co-expression in Claudin18.2 positive resectable gastroesophageal cancers
Presenter: Antonella Cammarota
Session: Poster session 22
1573P - Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC
Presenter: Baosheng Li
Session: Poster session 22
1575P - Factors associated with uptake of adjuvant nivolumab in a nationwide esophageal cancer patient cohort
Presenter: Rob Verhoeven
Session: Poster session 22
1577P - Prior antibiotic administration disrupts outcomes of PD-1 blockade in advanced gastric cancer by altering gut microbiome and systemic immune response
Presenter: Chang Gon Kim
Session: Poster session 22
1578P - Effect of immune checkpoint inhibitors in metastatic gastric cancer: A real-world evidence study
Presenter: Francesco Puccetti
Session: Poster session 22
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22